Navigation Links
Prix Galien USA Announces 2009 Final Candidates
Date:8/7/2009

Honorees for Best Pharmaceutical Agent, Best Biotechnology Product and Best Medical Technology to be recognized at Sept. 30 gala ceremony

NEW YORK, Aug. 7 /PRNewswire-USNewswire/ -- The 2009 Prix Galien USA will recognize innovative biopharmaceutical drugs and medical technologies that have made a deep impact on the quality of human life at a gala event on September 30. Candidates for the 2009 program provide relief to millions of people living with chronic diseases including cardiovascular disease and diabetes and treatments for people living with cancer and HIV/AIDS. The 2009 Prix Galien USA ceremony will again be emceed by Charlie Rose at the American Museum of Natural History in New York.

Final candidates for the Prix Galien USA 2009 awards are:

Best Pharmaceutical Agent:

  • AstraZeneca, CRESTOR(R)
  • Celgene, Vidaza(R)
  • Novartis Oncology, GLEEVEC(R)
  • Novartis Pharmaceuticals, EXELON(R)( )PATCH
  • Pfizer, Zyvox(R)
  • Schering-Plough, TEMODAR(R) and ZETIA(R)
  • Teva Neurosciences, AZILECT(R)
  • Wyeth, TORISEL(R)

Best Biotechnology Product:

  • Amgen, Nplate(R)
  • GlaxoSmithKline, PROMACTA(R) and Tykerb(R)
  • Schering-Plough, PEGINTRON(R)
  • Tibotec, INTELENCE(TM)
  • United Therapeutics, REMODULIN(R)
  • Wyeth, Prevnar (R)

Best Medical Device:

  • Abbott Vascular, XIENCE (R)
  • Boston Scientific, TAXUS (R)
  • DCA Design, Lantus(R)( )SoloSTAR(R)
  • GlaxoSmithKline, Veramyst(R)( )Mistpro(TM)
  • Veridex, CellSearch(R) CTC Test

"Nominees for the Prix Galien USA stand apart from other drugs and technologies in the marketpla
'/>"/>

SOURCE Prix Galien USA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Prix Galien USA Announces 2008 Final Candidates
2. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
3. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
4. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ceres, Inc . (Nasdaq: CERE ), an ... for the three months ended May 31, 2014 and ... reported that the company and its customers have made ... Brazil, which concluded in June, despite dry and hot ... part of the growing season. Yields of several of ...
(Date:7/10/2014)... today in the journal PNAS (Proceedings of the ... of day and sleep deprivation have a significant effect ... looking at the best time of day to test ... for administering medicines effectively. , Researchers from the University ... investigated the links between sleep deprivation, body clock disruption ...
(Date:7/10/2014)... geckos and spiders can sit upside down forever. Nanophysics makes ... this in an article just published in Physical Review ... , Geckos and spiders that seem to be able to ... researchers worldwide for many years. We will soon be able ... as the gecko,s foot. But the fact is, sooner or ...
(Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... allows up to 50% sucrose reduction while maintaining the sweet taste ... ... CA, July 29, 2008 Senomyx, Inc.,(Nasdaq: SNMX ), a ... flavor ingredients for the food, beverage,and ingredient supply industries, announced today ...
... technology to an,orphan disease, in a unique translational ... July 29 ,ALS Therapy Development Institute (ALS TDI) ... new collaboration aimed at advancing any potential,application of ... sclerosis,commonly known as Lou Gehrig,s diseases. The new ...
... Zenobia Therapeutics, Inc.,(Zenobia) announced today that ... from The Michael J. Fox Foundation for ... potential to,fundamentally alter the course of Parkinson,s ... Ross of Johns Hopkins University,Zenobia will discover ...
Cached Biology Technology:SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 2SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 3SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 4ALS Therapy Development Institute and California Stem Cell, Inc. Announce Long-Term Scientific Collaboration 2ALS Therapy Development Institute and California Stem Cell, Inc. Announce Long-Term Scientific Collaboration 3Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2
(Date:7/10/2014)... JUPITER, FL, July 10, 2014 Amidst the astounding ... of synaptic connections in the brain, how do nerve ... connections to build? How do they coordinate these events ... scientists from the Florida campus of The Scripps Research ... processes, showing that a particular protein plays a far ...
(Date:7/10/2014)... Amyloid diseases, such as Alzheimer,s disease, type 2 ... the common trait that proteins aggregate into long ... studies have found that neither the amylin monomer ... New evidence using two-dimensional infrared (2D IR) spectroscopy ... aggregation pathway that may explain toxicity, opening a ...
(Date:7/10/2014)... Ore. Nuclear engineers at Oregon State University have ... device that should help people all over the world ... intensity, and whether or not it poses a health ... to public demand following the nuclear incident in Fukushima, ... what level of radiation they were being exposed to ...
Breaking Biology News(10 mins):Scripps Florida scientists shed new light on nerve cell growth 2New technology reveals insights into mechanisms underlying amyloid diseases 2Sophisticated radiation detector designed for broad public use 2Sophisticated radiation detector designed for broad public use 3
... Lee Lovering, Ph.D., School of Biosciences, University of ... Award for his seminal work on the structural ... and modify cell walls in bacteria. Natalie Strynadka, ... Lovering,s work: "his spectacular abilities in structural biology ...
... 2012) Aeras and the Infectious Disease Research Institute ... trial of IDRI,s novel tuberculosis vaccine candidate, ID93 + ... safety, tolerability and immunogenicity of the vaccine candidate in ... by Johnson County Clin-Trials in Lenexa, Kansas, in close ...
... risks posed to people who work with tiny fibres used ... Research into the health risks posed by nanofibres ... has pinpointed the lengths at which these fibres are ... from a range of materials including carbon, are about 1,000 ...
Cached Biology News:The American Society for Microbiology honors Andrew Lovering 2As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing 2